参考文献/References:
[1]李丹燕,何健,朱斌,等.肝脏原发及转移性恶性肿瘤不同b值DWI的ADC值特点及变化趋势[J].实用放射学杂志,2013,29(12):1948-1952,1962.
[2]Tokgoz O,Unlu E,Unal I,et al.Diagnostic value of diffusion weighted MRI and ADC in differential diagnosis of cavernous hemangioma of the liver[J].Afr Health Sci,2016,16(1):227-233.
[3]Pieper CC,Meyer C,Sprinkart AM,et al.The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases[J].Onco Targets Ther 2016,9(Issue 1):4089-4098.
[4]Li X,Liang Q,Zhuang L,et al.Preliminary study of MR diffusion tensor imaging of the liver for the diagnosis of hepatocellular carcinoma[J].PLoS One,2015,10(8):e0135568.
[5]Testa ML,Chojniak R,Sene LS,et al.Is DWI ADC a useful tool in the characterization of focal hepatic lesions suspected of malignancy[J].PLoS One,2014,9(7):e101944.
[6]陶乙宣,范国光.磁共振扩散张量成像技术在脑肿瘤手术前后的临床应用价值[J].临床放射学杂志,2017,36(06):775-778.
[7]Erturk SM,Ichikawa T,Kaya E,et al.Diffusion tensor imaging of cysts,hemangimas,and metastases of the liver[J].Magn Reson Med,2015,73(4):1602-1608.
[8]赵广强,翁苓苓,陈义磊,等.弥散加权成像与弥散张量成像评价肝纤维化的实验研究[J].医学影像学杂志,2016,26(1):99-103.
[9]Lee Y,Kim H.Assessment of diffusion tensor MR imaging (DTI)in liver fibrosis with minimal confounding effect of hepatic steatosis[J].Magn Reson Med,2015,73(4):1602-1608.
[10]周卫兵,龚良庚,任海波,等.磁共振扩散张量成像在肝脏局灶性病变诊断中的应用[J].南昌大学学报(医学版),2014,54(3):18-21.
[11]陈丽华,刘爱连,宋清伟,等.磁共振扩散张量成像鉴别诊断肝内胆管细胞癌与肝细胞癌[J].中国医学影像技术,2017,33(07):993-997.
[12]刘奇志,谢晓奕,吴卫华,等.肺癌肝转移瘤二维超声表现与组织病理类型的相关研究[J].中国临床医学,2012,19(3):298-299.
[13]沈亚琪,胡道予,李建军等.DTI对两种肝纤维化动物模型的定量研究[J].放射学实践,2012,27(2):145-150.
[14]Tosun M,Inan N,Sarisoy HT,et al.Diagnostic performance of conventional diffusion weighted imaging and diffusion tensor imaging for the liver fibrosis and inflammation[J].Eur J Radiol,2013,82(2):203-207.
[15]张丽,胡道予,夏黎明,等.MR-DTI在肝硬化早期诊断中的应用价值[J].实用放射学杂志,2009,25(12):1748-1752.
[16]Wong OL,Gloh Lo G,Lee R,et al.The effect of respiratory and cardiac motion in liver diffusion tensor imaging(DTI)[J].J Comput Assist Tomogr,2014,38(3):352-359.
相似文献/References:
[1]郑德仁.多排螺旋CT诊断肝血管瘤及肝脏肿瘤的临床价值分析[J].医学信息,2018,31(20):160.[doi:10.3969/j.issn.1006-1959.2018.20.050]
ZHENG De-ren.Clinical Value of Multi-slice Spiral CT in Diagnosis of Hepatic Hemangioma and Liver Tumor[J].Journal of Medical Information,2018,31(09):160.[doi:10.3969/j.issn.1006-1959.2018.20.050]
[2]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(09):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[3]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Journal of Medical Information,2022,35(09):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[4]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(09):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[5]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Journal of Medical Information,2020,33(09):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[6]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(09):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
[7]杨孟涛,汪 艇,杜 伟,等.miR-181b-5p靶向调控SPP1在肝细胞癌中过表达的临床意义及作用机制[J].医学信息,2022,35(24):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
YANG Meng-tao,WANG Ting,DU Wei,et al.Clinical Significance and Mechanism of miR-181b-5p Targeting to Regulate SPP1 Overexpression in Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(09):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
[8]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Journal of Medical Information,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[9]唐 菀,张晓珣,柴 进.SLCO1B1在肝细胞癌中的表达及其对患者预后的影响[J].医学信息,2023,36(02):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
TANG Wan,ZHANG Xiao-xun,CHAI Jin.Expression of SLCO1B1 in Hepatocellular Carcinoma and its Effect on Prognosis[J].Journal of Medical Information,2023,36(09):12.[doi:10.3969/j.issn.1006-1959.2023.02.002]
[10]蒙建源,朱刚健.应用细胞免疫治疗肝细胞癌的研究[J].医学信息,2023,36(05):177.[doi:10.3969/j.issn.1006-1959.2023.05.037]
MENG Jian-yuan,ZHU Gang-jian.Study on Cellular Immunotherapy for Hepatocellular Carcinoma[J].Journal of Medical Information,2023,36(09):177.[doi:10.3969/j.issn.1006-1959.2023.05.037]